

SUPPLEMENTARY MATERIAL

Two new triterpenoids from *Gardenia jasminoides* fruits

Dan Lu^{a, #}, Weiyang Zhang^{d, #}, Yingnan Jiang^b, Yu Zhang^a, Dabo Pan^a, Dan Zhang^c, Xinsheng Yao^{a,*} and Yang Yu^{a,*}

^a Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drug Research, Jinan University, Guangzhou 510632, People's Republic of China

^b College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China

^c Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, People's Republic of China

^d Faculty of Chinese Medicine, Macau University of Science and Technology and State Key Laboratory of Quality Research in Chinese Medicine, Taipa, Macau, 999078, People's Republic of China

* To whom correspondence should be addressed. Tel: +86-20-85225849. Fax: +86-20-85221559. Email: tyaoxs@jnu.edu.cn (X.Y.), 1018yuyang@163.com (Y.Y.).

Both authors contributed equally to this research.

ABSTRACT

A new cycloartane triterpenoid, named gardenolic acid C (**1**), a new ursane triterpenoid, named $3\beta,16\beta,21\beta,23,24$ -pentahydroxy urs-12,18,20-trien-28-oic acid γ -lactone (**2**), together with three known triterpenoids, gardenolic acid A (**3**), gardenolic acid B (**4**), and $3\alpha,16\beta,23,24$ -tetrahydroxy-28-nor-ursane-12,17,19,21-tetraen (**5**) were isolated from the fruits of *Gardenia jasminoides* Ellis. The structures of these compounds were elucidated by analyses of spectroscopic data. All isolates were evaluated for their neuroprotective effects *in vitro*.

KEYWORDS

Gardeniae Fructus, gardenolic acid C, ursane-type triterpenoid, neuroprotective effect

List of Contents

Figure S1 HRESIMS spectrum of compound 1	4
Figure S2 ^1H -NMR spectrum of compound 1	4
Figure S3 ^{13}C -NMR spectrum of compound 1	5
Figure S4 DEPT-135 spectrum of compound 1	5
Figure S5 ^1H - ^1H COSY spectrum of compound 1	6
Figure S6 HSQC spectrum of compound 1	6
Figure S7 HMBC spectrum of compound 1	7
Figure S8 NOESY spectrum of compound 1	7
Figure S9 HRESIMS spectrum of compound 2	8
Figure S10 ^1H -NMR spectrum of compound 2	8
Figure S11 ^{13}C -NMR spectrum of compound 2	9
Figure S12 DEPT-135 spectrum of compound 2	9
Figure S13 ^1H - ^1H COSY spectrum of compound 2	10
Figure S14 HSQC spectrum of compound 2	10
Figure S15 HMBC spectrum of compound 2	11
Figure S16 NOESY spectrum of compound 2	11
Figure S17 ^1H - ^1H COSY (—) and key HMBC correlations (1a and 2a) NOESY correlations (1b and 2b) of compounds 1 and 2	12
Figure S18 Cell viabilities of MPP $^+$ -challenged SH-SY5Y cells, and effects of compounds 1, 3-5 (mean \pm SD %, n = 3), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, * vs. MPP $^+$ -challenged group.	12
Table S1 NMR spectroscopic data (in CD ₃ OD) of compounds 1 and 2	13

Supplementary Materials

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 mDa / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3




Figure S1 HRESIMS spectrum of compound 1




Figure S2 ¹H-NMR spectrum of compound 1




Figure S3 ¹³C-NMR spectrum of compound 1




Figure S4 DEPT-135 spectrum of compound 1




Figure S5 ¹H-¹H COSY spectrum of compound 1




Figure S6 HSQC spectrum of compound 1




Figure S7 HMBC spectrum of compound 1




Figure S8 NOESY spectrum of compound 1

Single Mass Analysis

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions



99 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 30-65 H: 0-100 O: 0-15 Na: 0-1

GJ-5L4A

2017051553 161 (1.305)

1: TOF MS ES+
1.60e+004**Figure S9 HRESIMS spectrum of compound 2****Figure. S10 ¹H-NMR spectrum of compound 2**




Figure S11 ^{13}C -NMR spectrum of compound 2




Figure S12 DEPT-135 spectrum of compound 2




Figure S13 ¹H-¹H COSY spectrum of compound 2




Figure S14 HSQC spectrum of compound 2




Figure S15 HMBC spectrum of compound 2




Figure S16 NOESY spectrum of compound 2




Figure S17. ^1H - ^1H COSY (—) and key HMBC correlations (1a and 2a) NOESY correlations (1b and 2b) of compounds **1** and **2**.




Figure S18. Cell viabilities of MPP⁺-challenged SH-SY5Y cells, and effects of compounds **1**, **3-5** (mean \pm SD %, $n = 3$), * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, * vs. MPP⁺-challenged group.

Table S1. NMR spectroscopic data (in CD₃OD) of compounds **1** and **2**

No.	1		2	
	δ_{C}	δ_{H} (<i>J</i> in Hz)	δ_{C}	δ_{H} (<i>J</i> in Hz)
1	32.8	1.32	39.7	1.73, 1.05
2	30.5	1.75, 1.64	28.0	1.82, 1.73
3	76.3	4.04 (dd, 11.4, 4.5)	74.6	3.76, dd (11.8, 4.5)
4	55.8		47.3	
5	45.7	1.96	49.1	1.32
6	24.1	1.24, 0.99	19.5	1.67, 1.53
7	26.8	1.33, 1.16	34.3	1.59
8	49.3	1.62	40.4	
9	21.1		49.2	1.61
10	26.4		37.6	
11	27.5	2.05	24.3	2.09
12	34.0	1.66	128.5	5.38, dd (4.7, 2.7)
13	46.5		137.6	
14	50.0		44.4	
15	36.6	1.36	39.1	1.99, dd (13.7, 3.6) 1.08, t (13.7)
16	29.1	1.96, 1.51	67.3	4.24, dd (13.7, 3.6)
17	53.4	1.64	55.7	
18	18.6	1.03, s	139.4	
19	30.7	0.61, d (4.2), 0.43, d (4.2)	144.0	
20	38.0	1.51	129.2	
21	18.9	0.90, d (6.5)	81.9	5.10, d (5.5)
22	40.8	2.28, 1.84	35.2	2.59, dd (11.0, 5.5), 1.90, d (11.0)
23	130.1	5.66	63.2	4.07, d (11.4), 3.68, d (11.4)
24	135.5	6.12, d (15.6)	63.6	4.12, d (11.5), 3.59, d (11.5)
25	143.4		16.9	1.03, s
26	114.5	4.84	17.1	1.10, s
27	18.9	1.83, s	26.8	1.00, s
28	181.2		178.5	
29	10.0	1.10, s	14.3	1.87, s
30	19.7	0.94, s	114.1	5.31, s, 5.24, s

Multiplets or overlapped signals are reported without designating multiplicity